Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development

Thumbnail Image
Date
2020
Authors
Marx, Uwe
Akabane, Takafumi
Andersson, Tommy B.
Baker, Elizabeth
Beilmann, Mario
Beken, Sonja
Brendler-Schwaab, Susanne
Editors
Contact
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
DOI (citable link)
ArXiv-ID
International patent number
Link to the license
EU project number
681002
Project
EUToxRisk21
Open Access publication
Collections
Restricted until
Title in another language
Research Projects
Organizational Units
Journal Issue
Publication type
Journal article
Publication status
Published
Published in
Alternatives to Animal Experimentation : ALTEX ; 37 (2020), 3. - Springer Spektrum. - ISSN 1868-596X. - eISSN 1868-8551
Abstract
The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human (patho)biology in vitro and, therefore, provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Nowadays, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which says this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches have neither been widely adopted by the pharmaceutical industry yet nor reached regulated drug authorization processes at all.

Here, 46 leading experts from all stakeholders - academia, MPS supplier industry, pharmaceutical and consumer products industries, and leading regulatory agencies - worldwide have analyzed existing challenges and hurdles along the MPS-based assay life cycle in a second workshop of this kind in June 2019. They identified that the level of qualification of MPS-based assays for a given context of use and a communication gap between stakeholders are the major challenges for industrial adoption by end-users. Finally, a regulatory acceptance dilemma exists against that background. This t4 report elaborates on these findings in detail and summarizes solutions how to overcome the roadblocks. It provides recommendations and a roadmap towards regulatory accepted MPS-based models and assays for patients' benefit and further laboratory animal reduction in drug development. Finally, experts highlighted the potential of MPS-based human disease models to feedback into laboratory animal replacement in basic life science research.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690MARX, Uwe, Takafumi AKABANE, Tommy B. ANDERSSON, Elizabeth BAKER, Mario BEILMANN, Sonja BEKEN, Susanne BRENDLER-SCHWAAB, Thomas HARTUNG, Marcel LEIST, Giorgia PALLOCCA, 2020. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. In: Alternatives to Animal Experimentation : ALTEX. Springer Spektrum. 37(3). ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.2001241
BibTex
@article{Marx2020Biolo-49035,
  year={2020},
  doi={10.14573/altex.2001241},
  title={Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development},
  number={3},
  volume={37},
  issn={1868-596X},
  journal={Alternatives to Animal Experimentation : ALTEX},
  author={Marx, Uwe and Akabane, Takafumi and Andersson, Tommy B. and Baker, Elizabeth and Beilmann, Mario and Beken, Sonja and Brendler-Schwaab, Susanne and Hartung, Thomas and Leist, Marcel and Pallocca, Giorgia}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/49035">
    <dc:creator>Baker, Elizabeth</dc:creator>
    <dc:contributor>Akabane, Takafumi</dc:contributor>
    <dc:contributor>Andersson, Tommy B.</dc:contributor>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/49035/1/Marx_2-tqyy3cykvifs8.pdf"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/49035/1/Marx_2-tqyy3cykvifs8.pdf"/>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:title>Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development</dcterms:title>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:contributor>Baker, Elizabeth</dc:contributor>
    <dc:contributor>Beilmann, Mario</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Beilmann, Mario</dc:creator>
    <dc:creator>Leist, Marcel</dc:creator>
    <dcterms:abstract xml:lang="eng">The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human (patho)biology in vitro and, therefore, provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Nowadays, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which says this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches have neither been widely adopted by the pharmaceutical industry yet nor reached regulated drug authorization processes at all.&lt;br /&gt;&lt;br /&gt;Here, 46 leading experts from all stakeholders - academia, MPS supplier industry, pharmaceutical and consumer products industries, and leading regulatory agencies - worldwide have analyzed existing challenges and hurdles along the MPS-based assay life cycle in a second workshop of this kind in June 2019. They identified that the level of qualification of MPS-based assays for a given context of use and a communication gap between stakeholders are the major challenges for industrial adoption by end-users. Finally, a regulatory acceptance dilemma exists against that background. This t4 report elaborates on these findings in detail and summarizes solutions how to overcome the roadblocks. It provides recommendations and a roadmap towards regulatory accepted MPS-based models and assays for patients' benefit and further laboratory animal reduction in drug development. Finally, experts highlighted the potential of MPS-based human disease models to feedback into laboratory animal replacement in basic life science research.</dcterms:abstract>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Beken, Sonja</dc:creator>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-03-13T11:52:59Z</dcterms:available>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Brendler-Schwaab, Susanne</dc:creator>
    <dc:language>eng</dc:language>
    <dc:contributor>Beken, Sonja</dc:contributor>
    <dc:creator>Akabane, Takafumi</dc:creator>
    <dc:creator>Andersson, Tommy B.</dc:creator>
    <dcterms:issued>2020</dcterms:issued>
    <dc:contributor>Pallocca, Giorgia</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Pallocca, Giorgia</dc:creator>
    <dc:creator>Marx, Uwe</dc:creator>
    <dc:contributor>Brendler-Schwaab, Susanne</dc:contributor>
    <dc:contributor>Marx, Uwe</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-03-13T11:52:59Z</dc:date>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/49035"/>
  </rdf:Description>
</rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Contact
URL of original publication
Test date of URL
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
Yes
Refereed
Yes